Mechanisms of Berberine for the Treatment of Atherosclerosis Based on Network Pharmacology

Xuejiao Xie1, Xingyu Ma1, Siyu Zeng1

  • 1Department of Zhongjing Theory, College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China.

Insights

Berberine shows promise in treating atherosclerosis by inhibiting inflammation and cell proliferation. This study used network pharmacology to uncover berberine

Area of Science:

  • Pharmacology and Traditional Chinese Medicine
  • Cardiovascular Disease Research
  • Systems Biology Approaches

Background:

  • Atherosclerosis is a metabolic disease involving lipid disorders and plaque formation.
  • Current treatments for atherosclerosis have adverse effects, necessitating new therapeutic options.
  • Berberine, a natural product from traditional Chinese medicine, is a potential candidate for atherosclerosis treatment.

Purpose of the Study:

  • To investigate the comprehensive mechanism of berberine in treating atherosclerosis using network pharmacology.
  • To identify key molecular targets and pathways involved in berberine's action against atherosclerosis.
  • To provide a theoretical basis for berberine as a novel therapeutic agent for atherosclerosis.

Main Methods:

  • Network pharmacology was employed to analyze interactions between berberine and atherosclerosis.
  • Databases were used to identify berberine and atherosclerosis-related targets.
  • Protein-protein interaction (PPI) networks were constructed and merged to find core targets.
  • Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed.

Main Results:

  • A total of 31 berberine targets and 331 atherosclerosis targets were identified.
  • A core PPI network with 132 nodes and 3339 edges was constructed.
  • Functional enrichment analysis revealed associations with cell cycle regulation (G1/S transition).
  • Key KEGG pathways included cell cycle, ubiquitin-mediated proteolysis, MAPK, and PI3K-Akt signaling.

Conclusions:

  • Berberine appears to exert its anti-atherosclerosis effects by modulating cell cycle progression and inhibiting inflammation.
  • The identified pathways provide insights into berberine's therapeutic mechanisms.
  • This study supports berberine as a promising natural compound for atherosclerosis treatment.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
265
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
816
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
667
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.2K
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
280
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.2K